Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Will newer tyrosine kinase inhibitors have an impact in AML?Levis MJBest Pract Res Clin Haematol 2010[Dec]; 23 (4): 489-94FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3 mutations were discovered to have a role in AML. Several FLT3 inhibitors have been developed in the last several years, beginning with less potent, less selective agents. The newer FLT3 inhibitors appear to be more potent in vivo and have shown more promise than the older agents in monotherapy trials.|*Leukemia, Myeloid, Acute/drug therapy/enzymology/genetics[MESH]|*Mutation[MESH]|Clinical Trials as Topic[MESH]|Humans[MESH]|Protein Kinase Inhibitors/*therapeutic use[MESH]|fms-Like Tyrosine Kinase 3/*antagonists & inhibitors/*genetics[MESH] |
